Several PI3K inhibitors have been developed to treat breast cancer (alpelisib), follicular lymphoma (copanlisib), and chronic lymphocytic leukemia (idelalisib). The gene discussed is PIK3CA; the disease is B-cell chronic lymphocytic leukemia.